Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nobelpharma, VLP Therapeutics Ink MOU for Malaria/Dengue Vaccine Collaboration
January 5, 2022
- Daiichi Sankyo’s EZH1/2 Inhibitor Filed for ATL in Japan
January 5, 2022
- 5 Atopic Dermatitis Drugs Debut in Japan since 2018; Focus Now on Roles of Dupixent, JAK Inhibitors
December 28, 2021
- Chugai Joins NCC Study for Asia-Prevalent Cancers
December 28, 2021
- Shionogi Gets Commercial Rights to Susmed’s Insomnia App
December 28, 2021
- Shionogi Launches Global PIII for COVID-19 Vaccine
December 28, 2021
- Daiichi Sankyo’s HER3 ADC Gets Breakthrough Therapy Tag in US
December 27, 2021
- Sosei Gets US$100 Million from Neurocrine as Deal Clears Antitrust Hurdles
December 27, 2021
- Daiichi Sankyo Kicks Off PIII for Enhertu in Frontline NSCLC
December 27, 2021
- Eisai’s Lecanemab Bags Fast-Track Status in US
December 27, 2021
- Kissei Files Rovatirelin for Spinocerebellar Degeneration in Japan
December 24, 2021
- Zogenix Files Dravet Syndrome Drug in Japan
December 23, 2021
- Takeda’s Eosinophilic Esophagitis Drug Rejected in US
December 23, 2021
- Kyowa Kirin, InveniAI Expand Collaboration in AI-Driven Drug Discovery
December 23, 2021
- Meiji to Launch Japan PIb/II of Hiyasta for B-cell Non-Hodgkin’s Lymphoma
December 23, 2021
- Ono Extends Drug Discovery Collaboration with Vanderbilt University in CNS
December 23, 2021
- Linepharma Submits NDA for Abortion Pills in Japan
December 23, 2021
- ITP Drug Fostamatinib Yields Positive Data in Japan PIII, Submission Eyed in 1st Half of 2022: Kissei
December 22, 2021
- Toray and 3SBio File NDA for Antipruritic Drug in China
December 22, 2021
- Actemra Production Has Doubled Since Start of COVID-19 Pandemic: Chugai CEO
December 22, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…